02448nas a2200409 4500008004100000022001400041245009600055210006900151260001300220300001300233490000700246520125300253653002201506653000901528653002201537653001501559653002301574653004001597653001101637653001701648653001801665653000901683653003601692653002401728653002401752653001701776100002301793700001901816700002301835700002501858700002001883700002501903700002801928700002301956700002301979856003602002 2009 eng d a1573-722500aC-reactive protein, interleukin-6, and prostate cancer risk in men aged 65 years and older.0 aCreactive protein interleukin6 and prostate cancer risk in men a c2009 Sep a1193-2030 v203 a

Inflammation is believed to play a role in prostate cancer (PCa) etiology, but it is unclear whether inflammatory markers C-reactive protein (CRP) and interleukin-6 (IL-6) associate with PCa risk in older men. Using Cox regression, we assessed the relationship between baseline concentrations of CRP and IL-6 and the subsequent PCa risk in the Cardiovascular Health Study, a population-based cohort study of mostly European American men of ages >64 years (n = 2,234; mean follow-up = 8.7 years; 215 incident PCa cases). We also tested associations between CRP and IL-6 tagSNPs and PCa risk, focusing on SNPs that are known to associate with circulating CRP and/or IL-6. Neither CRP nor IL-6 blood concentrations was associated with PCa risk. The C allele of IL-6 SNP rs1800795 (-174), a known functional variant, was associated with increased risk in a dominant model (HR = 1.44; 95% CI = 1.03-2.01; p = 0.03), but was not statistically significant after accounting for multiple tests (permutation p = 0.21). Our results suggest that circulating CRP and IL-6 do not influence PCa risk. SNPs at the CRP locus are not associated with PCa risk in this cohort, while the association between rs1800795 and PCa risk warrants further investigation.

10aAfrican Americans10aAged10aAged, 80 and over10aBiomarkers10aC-Reactive Protein10aEuropean Continental Ancestry Group10aHumans10aInflammation10aInterleukin-610aMale10aPolymorphism, Single Nucleotide10aProspective Studies10aProstatic Neoplasms10aRisk Factors1 aPierce, Brandon, L1 aBiggs, Mary, L1 aDeCambre, Marvalyn1 aReiner, Alexander, P1 aLi, Christopher1 aFitzpatrick, Annette1 aCarlson, Christopher, S1 aStanford, Janet, L1 aAustin, Melissa, A uhttps://chs-nhlbi.org/node/108402627nas a2200277 4500008004100000022001400041245009500055210006900150260001600219520176300235100002201998700001702020700002702037700002102064700002202085700001802107700002502125700002102150700002502171700002102196700002002217700002702237700002502264700002402289856003602313 2017 eng d a1546-415600aCoronary Artery Bypass Graft Surgery and Dementia Risk in the Cardiovascular Health Study.0 aCoronary Artery Bypass Graft Surgery and Dementia Risk in the Ca c2017 Mar 033 a

INTRODUCTION: The association between history of coronary artery bypass graft surgery (CABG) and dementia risk remains unclear.

METHODS: We conducted a prospective cohort analysis using data on 3155 elderly adults free from prevalent dementia from the US population-based Cardiovascular Health Study (CHS) with adjudicated incident all-cause dementia, Alzheimer disease (AD), vascular dementia (VaD), and mixed dementia.

RESULTS: In the CHS, the hazard ratio (HR) for all-cause dementia was 1.93 [95% confidence interval (CI), 1.36-2.74] for those with CABG history compared with those with no CABG history after adjustment for potential confounders. Similar HRs were observed for AD (HR=1.71; 95% CI, 0.98-2.98), VaD (HR=1.42; 95% CI, 0.56-3.65), and mixed dementia (HR=2.73; 95% CI, 1.55-4.80). The same pattern of results was observed when these CHS findings were pooled with a prior prospective study, the pooled HRs were 1.96 (95% CI, 1.42-2.69) for all-cause dementia, 1.71 (95% CI, 1.04-2.79) for AD and 2.20 (95% CI, 0.78-6.19) for VaD.

DISCUSSION: Our results suggest CABG history is associated with long-term dementia risk. Further investigation is warranted to examine the causal mechanisms which may explain this relationship or whether the association reflects differences in coronary artery disease severity.This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc-nd/4.0/.

1 aKuźma, Elżbieta1 aAirdrie, Jac1 aLittlejohns, Thomas, J1 aLourida, Ilianna1 aThompson-Coon, Jo1 aLang, Iain, A1 aScrobotovici, Monica1 aThacker, Evan, L1 aFitzpatrick, Annette1 aKuller, Lewis, H1 aLopez, Oscar, L1 aLongstreth, William, T1 aUkoumunne, Obioha, C1 aLlewellyn, David, J uhttps://chs-nhlbi.org/node/734802769nas a2200229 4500008004100000022001400041245013000055210006900185260001600254520199500270100002802265700002602293700002302319700002002342700002502362700002502387700002002412700002202432700002502454700002402479856003602503 2024 eng d a2152-525000aCirculating Ketone Bodies, Pyruvate, and Citrate and Risk of Cognitive Decline, Structural Brain Abnormalities, and Dementia.0 aCirculating Ketone Bodies Pyruvate and Citrate and Risk of Cogni c2024 Nov 083 a

The relationship between key energy metabolites and brain health is not well understood. We investigated the association between circulating ketone bodies, pyruvate, and citrate with cognitive decline, structural brain characteristics, and risk of dementia. We measured ketone bodies (acetoacetate, β-hydroxybutyrate, and acetone), pyruvate, and citrate species using NMR in plasma samples from 1,850 older adults in the Cardiovascular Health Study collected in 1989-90 or 1992-93. Cognitive decline was assessed using the modified Mini-Mental State Examination and the Digit Symbol Substitution Test. Dementia was adjudicated by a committee of experts through comprehensive evaluations including cognitive tests, medical records, and interviews with the next of kin. Dementia-related mortality was confirmed by a committee using death certificates and other clinical data from hospitalization. Multivariable linear mixed models were used to assess 9-year cognitive decline, while multivariable Cox regression models evaluated 6-year dementia incidence and 22-year dementia-related mortality. White matter lesions and ventricular size were measured using MRI in 1992-94 and were analyzed using multivariable linear regression models. Higher plasma levels of ketones, particularly β-hydroxybutyrate, were associated with faster cognitive decline (β, -0.10; 95% CI, -0.15 to -0.05; P&;lt.001) and dementia-related mortality (HR per SD, 1.29; 95% CI, 1.07 to 1.56; P=0.023). Higher pyruvate concentrations were associated with slower cognitive decline, smaller ventricular size, lower dementia risk (HR per SD, 0.87; 95% CI, 0.77 to 0.97; P=0.013; P=0.073), and lower dementia mortality. Higher citrate levels were associated with less cognitive decline and lower dementia risk. In adults aged 65 years and older, circulating ketone bodies are associated with faster cognitive decline and higher dementia mortality, while pyruvate and citrate are associated with lower dementia risk.

1 aGutierrez-Tordera, Laia1 aMoseholm, Kristine, F1 aTrius-Soler, Marta1 aBulló, Mònica1 aFitzpatrick, Annette1 aConnelly, Margery, A1 aLopez, Oscar, L1 aJensen, Majken, K1 aGuasch-Ferré, Marta1 aMukamal, Kenneth, J uhttps://chs-nhlbi.org/node/9850